NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development
Visara Secures Exclusive Option for Potential Acquisition of YOL104-2 for Ocular Surface Squamous Neoplasia
Visara Expands Ophthalmology Pipeline with Exclusive License for Investigational Nerve Growth Factor Therapy for Neurotrophic Keratitis
NovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026
NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution
NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026
NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer
Cerrado Gold Acquires the Past-Producing Manantial Espejo Mine in Santa Cruz, Argentina, from Pan American Silver
Triumph Gold Announces Strategic Review of Non-Core Exploration Projects and $15 Million Private Placement